Loading…
Employees: 1,462
Size Shofu (7979.T) is a Japan Health Care company (Medical Specialties) with a market value of $475M, the 1098th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥2,101 on 6 Nov 2026.
Performance Over six months the shares gained 27.2%, against -14.2% for the median peer and +1.8% for the Japan market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 6.5% over the last twelve months (peer median +0.6%); the operating margin is 13.8% (peer median 6.3%).
Valuation It trades at 12.2× forward earnings against a peer median of 22.6× (3rd cheapest of 11).
Capital Return on invested capital runs 4.4 points above its cost of capital (5.4% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥41.3B | ¥40.0B | ¥38.7B | ¥35.1B | ¥31.7B |
| Revenue growth | — | +3% | +10% | +11% | — |
| Gross profit | ¥24.7B | ¥23.7B | ¥23.0B | ¥21.0B | ¥18.7B |
| EBITDA | ¥6.94B | ¥6.44B | ¥6.45B | ¥5.88B | ¥4.80B |
| Net income | ¥6.18B | ¥4.89B | ¥4.32B | ¥3.66B | ¥3.14B |
| Free cash flow | n/a | -¥62.0M | ¥2.22B | ¥1.47B | ¥1.62B |
| Capital expenditure | n/a | ¥3.60B | ¥1.32B | ¥1.71B | ¥1.63B |
| Total debt | ¥1.32B | ¥257M | ¥213M | ¥457M | ¥1.34B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7979.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.4% | -4.6% | 7th lowest of 21 |
| 6-month return | +27.2% | -14.2% | 5th highest of 21 |
| Distance from 52-week high | -13.2% | -36.7% | 3rd highest of 21 |
| Revenue growth (TTM) | +6.5% | +0.6% | 6th highest of 21 |
| Operating margin | 13.8% | 6.3% | 6th highest of 21 |
| Forward P/E | 12.2× | 22.6× | 3rd cheapest of 11 |
| ROIC minus cost of capital | +4.4 pp | -2.5 pp | 6th highest of 18 |
| EV / EBITDA | 9.2× | 25.3× | 2nd cheapest of 5 |
| Net debt / EBITDA | -1.6× | -0.8× | 4th least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shofu 7979.T | Japan | $475M | +27% | +7% | 14% | 12.2× | n/a | n/a |
| Shanghai Kindly Enterprises Development 603987.SS | China | $474M | -14% | 0% | 11% | n/a | 3.8% | -2.8% |
| Guangdong Shirongzhaoye 002016.SZ | China | $473M | -28% | -31% | 3% | n/a | 22.2% | -11.7% |
| China Isotope & Radiation 1763.HK | Hong Kong | $478M | -38% | -5% | 13% | 6.7× | n/a | n/a |
| Huaren Pharmaceutical 300110.SZ | China | $472M | -16% | -3% | 6% | n/a | 6.7% | +0.3% |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $471M | +40% | +5% | 11% | 38.6× | 22.1% | +2.2% |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $470M | +35% | -5% | 2% | n/a | 42.6% | +0.4% |
| Beijing Leadman Biochemistry 300289.SZ | China | $483M | -11% | -6% | -12% | n/a | 35.5% | -6.9% |
| MiMedx MDXG | United States | $483M | -8% | -23% | -8% | 59.1× | 11.5% | +11.0% |
| CellaVision CEVI.ST | Sweden | $485M | +68% | +2% | 23% | 31.8× | 6.5% | +10.0% |
| WELL LEAD MEDICAL 603309.SS | China | $486M | -19% | +1% | 15% | 12.2× | -5.6% | +7.7% |
| Jenscare Scientific 9877.HK | Hong Kong | $463M | -32% | +993% | -106% | n/a | n/a | n/a |
| AngioDynamics ANGO | United States | $493M | +5% | +8% | -6% | n/a | n/a | n/a |
| Revenio REG1V.HE | Finland | $494M | -22% | +16% | 14% | 18.5× | 19.3% | +12.4% |
| Eiken Chemical 4549.T | Japan | $454M | -29% | +4% | 6% | 23.6× | n/a | n/a |
| Hunan Sundy Science and Technology 300515.SZ | China | $453M | -13% | +10% | 27% | 14.1× | 0.9% | +15.6% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $499M | -14% | -9% | -51% | n/a | n/a | n/a |
| PROTEINA 468530.KS | South Korea | $450M | -2% | -59% | -1,178% | n/a | n/a | n/a |
| Brainsway Ltd Sponsored ADR BWAY | United States | $450M | -35% | +32% | 12% | 27.4× | 34.3% | +18.8% |
| Chison Medical Technologies 688358.SS | China | $443M | -16% | -1% | 19% | 21.6× | 11.8% | +5.6% |
| AVITA Medical RCEL | United States | $513M | +304% | +1% | -47% | n/a | n/a | n/a |